Kissei Wins Japan Approval for Oral GnRH Antagonist Yselty for Uterine Fibroids

Kissei Pharmaceutical Co ( (JP:4547) ) has issued an announcement.

Kissei Pharmaceutical has obtained Japanese manufacturing and marketing authorization for Yselty Tablets 100 mg (linzagolix choline), an oral GnRH antagonist indicated for the treatment of uterine fibroids, following successful domestic Phase III trials. The drug, which reduces estrogen production by blocking GnRH receptors in the pituitary gland, is intended to improve symptoms such as excessive menstruation, pain, and anemia in a condition that affects more than 70% of women and contributes significantly to lost labor productivity in Japan. Kissei is preparing to launch Yselty domestically while similar launches and developments proceed through partners in Europe, Taiwan, South Korea, and Canada, positioning the product as a new treatment option in women’s health and reinforcing the company’s international footprint, with no immediate change to its current fiscal-year earnings forecast.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4900.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

More about Kissei Pharmaceutical Co

Kissei Pharmaceutical Co., Ltd., listed on the Tokyo Stock Exchange Prime Market, is a Japan-based drug maker that discovers and develops proprietary pharmaceuticals, with a focus on women’s health. The company is advancing its portfolio of endocrine-related treatments, including GnRH antagonists, and is pursuing both domestic commercialization and overseas licensing to partners in Europe, Asia, and North America.

YTD Price Performance: 13.93%

Average Trading Volume: 67,205

Technical Sentiment Signal: Buy

Current Market Cap: Yen188.3B

For a thorough assessment of 4547 stock, go to TipRanks’ Stock Analysis page.